Good morning :)
$
₹
Attovia Therapeutics, Inc. Common Stock

Attovia Therapeutics, Inc. Common Stock

ATTO

NASDAQ
Asset Logo

Attovia Therapeutics, Inc. Common Stock

ATTO

NASDAQ
$22.082.85% (-0.65)
$
₹
$22.082.85% (-0.65)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.0B the stock is ranked 2746

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.52
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
0 analyst
Hold
1 analyst
Sell
0 analyst

Analysts expect a -58.21% price downside over the next year

Current Price$22.08
Target Price$9.5

Company Profile

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.

Peers

Peers

MSA Safety
MSA
MSA Safety
P/E Ratio
22.22
22.22
1Y Return
5.67%
5.67%
Buy Reco %
60.00
60.00
HNI Corp
HNI
HNI Corp
P/E Ratio
—
—
1Y Return
1.95%
1.95%
Buy Reco %
100.00
100.00
Pitney Bowes Inc
PBI
Pitney Bowes Inc
P/E Ratio
14.08
14.08
1Y Return
46.65%
46.65%
Buy Reco %
20.00
20.00
Interface Inc
TILE
Interface Inc
P/E Ratio
13.91
13.91
1Y Return
14.65%
14.65%
Buy Reco %
100.00
100.00
MillerKnoll Inc
MLKN
MillerKnoll Inc
P/E Ratio
15.88
15.88
1Y Return
1.07%
1.07%
Buy Reco %
0.00
0.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Attovia Therapeutics, Inc. Common Stock -0-
MSA Safety22.224.930.98
HNI Corp-1.830.48

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-15.1
-14.4
-18.6
0.4
-20.6
Q1 2025
Q2 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2025Q2 2025Q1 2026Q2 2026
Total Revenue0000.45
Net Income-15.15-14.43-18.65-20.68
Net Profit Margin----4597.11%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Attovia Therapeutics, Inc. Common Stock (ATTO) share price today is $22.08 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $25.07 and a day low of $22.08.

  2. Attovia Therapeutics, Inc. Common Stock stock trades on NASDAQ under the ticker symbol ATTO.

  3. Attovia Therapeutics, Inc. Common Stock's market capitalization is $1.01B as of September 19, 2026 at 1:30 AM IST.

  4. Attovia Therapeutics, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of September 18, 2026.

  5. Attovia Therapeutics, Inc. Common Stock's price-to-book (P/B) ratio is 0 as of September 18, 2026.

  6. Yes, You can buy Attovia Therapeutics, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Attovia Therapeutics, Inc. Common Stock shares in three steps: 1. Search Attovia Therapeutics, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Attovia Therapeutics, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Attovia Therapeutics, Inc. Common Stock (ATTO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4528 shares at the current price of $22.08.

Loading...